Analyst Price Targets — CYRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2025 2:29 pm | — | UBS | $12.50 | $8.75 | TheFly | Cryoport price target raised to $12.50 from $11 at UBS |
| September 18, 2025 11:33 am | — | BTIG | $15.00 | $8.90 | TheFly | Cryoport price target raised to $15 from $10 at BTIG |
| April 1, 2025 11:47 am | — | UBS | $11.00 | $6.09 | TheFly | Cryoport price target raised to $11 from $10 at UBS |
| March 24, 2025 10:26 am | — | UBS | $10.00 | $7.10 | TheFly | Cryoport upgraded to Buy from Neutral at UBS |
| December 19, 2024 12:06 pm | Subbu Nambi | Guggenheim | $11.00 | $7.62 | TheFly | Cryoport initiated with a Buy at Guggenheim |
| August 7, 2024 6:26 am | Matthew Stanton | Jefferies | $8.00 | $7.79 | TheFly | Cryoport downgraded to Hold at Jefferies on diminished growth outlook |
| July 31, 2024 3:29 am | Yuan Zhi | B.Riley Financial | $15.00 | $9.05 | StreetInsider | B.Riley Upgrades CryoPort (CYRX) to Buy |
| May 3, 2024 3:46 am | Yuan Zhi | B.Riley Financial | $19.00 | $15.95 | StreetInsider | B.Riley Downgrades CryoPort (CYRX) to Neutral |
| April 4, 2024 4:09 am | Matthew Stanton | Jefferies | $21.00 | $18.34 | StreetInsider | Jefferies Assumes CryoPort (CYRX) at Buy, 'Thesis Refresh' |
| March 13, 2024 6:36 am | David Saxon | Needham | $18.00 | $14.36 | StreetInsider | CryoPort (CYRX) PT Lowered to $18 at Needham |
Latest News for CYRX
Cryoport receives a buy rating with a $9.1 price target, implying 17% upside by FY 2026. CYRX demonstrated double-digit revenue growth in Q4 2025, led by Life Sciences Services, and improved gross margins to 47.8%. Management targets positive adjusted EBITDA in H2 2026, supported by cost reductions and a strengthened partnership with DHL.
CryoPort, Inc. (NASDAQ: CYRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.42 per share a year ago.
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CYRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.